共 538 条
[1]
Saisho Y(2018)Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative bacteria, in healthy subjects Antimicrob Agents Chemother 62 e02163-e02117
[2]
Katsube T(2018)Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters Eur J Clin Pharmacol 74 931-938
[3]
White S(2018)Humanized exposures of cefiderocol, a siderophore cephalosporin, display sustained in vivo activity against siderophore-resistant Pseudomonas aeruginosa Pharmacology 101 278-284
[4]
Fukase H(2016)In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria J Antimicrob Chemother 71 670-677
[5]
Shimada J(2016)In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains Antimicrob Agents Chemother 60 729-734
[6]
Katsube T(2018)Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial Lancet Infect Dis 18 1319-1328
[7]
Miyazaki S(2018)Successful treatment of ventriculitis caused by Am J Health Syst Pharm 75 953-957
[8]
Narukawa Y(2018) and carbapenem-resistant J Antimicrob Chemother 73 3170-3175
[9]
Hernandez-Illas M(2018) with i.v. ceftazidime–avibactam and intrathecal amikacin J Glob Antimicrob Resist 15 136-139
[10]
Wajima T(2018)Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae BMJ Case Rep 2018 bcr-2018-bc225440